Long-term treatment with high-dosage XXXX in advanced @entity191 .

@entity1 @entity2847 @entity304 @entity935 @entity910 @entity191
Long-term follow-up indicated that levodopa as a replacement therapy merely improves the @entity304 , and does so for only a limited number of years. The reason for this tachyphylaxis or declining efficacy in levodopa therapy and the increasing number and intensity of various distressing difficulties in the management of @entity191 , such as @entity910 and on-off phenomena, is the main subject of many recent studies. It is still widely accepted that levodopa provides the best therapeutic tool for @entity191 . @entity2847 , an ergot derivative, is the main clinically used @entity935 agonist, and it has been established as a valuable adjunct in the treatment of @entity191 . @entity2847 is most useful in @entity1 with a declining efficacy of levodopa treatment, in @entity1 with diurnal oscillations in motor performance, especially in @entity1 with wearing-off phenomena, and in @entity1 with onset and end-of-dose @entity910 . The question of @entity2847 dosage, required to obtain an optimal benefit and a decreased rate of late adverse reactions, is quite controversial. The trend has been to lower daily dosage of @entity2847 , i.e., low doses suffice in @entity1 with mild, early disease. Higher doses of @entity2847 seem to be required in @entity1 with severe @entity191 . In this retrospective study of 8 years experience with high dosage of @entity2847 in levodopa response-losing @entity191 @entity1 , the adjunction of @entity2847 had a clear-cut but short-lasting beneficial effect on the disability scores.(ABSTRACT TRUNCATED AT 250 WORDS)
